BACKGROUND AND PURPOSE Thrombolytic therapy rate for acute ischemic stroke remains low, and improving public awareness of thrombolytic therapy may be helpful to reduce delay and increase chances of thrombolytic therapy. Our purpose was to survey the level of knowledge about thrombolytic therapy for acute ischemic stroke among community residents in Yuzhong district, Chongqing, China. METHODS ...

The ability of thrombolytic therapy to lower mortality in patients with acute myocardial infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. In the ensuing 10 years, large efforts have been undertaken to develop more effective and safer thrombolytic agents. In addition, the value of adjunctive agents influencing thrombotic...

Despite the fact that magnetic thrombolytic composites is an emerging area, all known so far systems are based on the similar mechanism of action: thrombolytic enzyme releases from the magnetic carrier leaving non-active matrix, thus making the whole system active only for a limited period of time. Such systems often have very complex structure organization and composition, consisting of materi...

OBJECTIVE To examine use of thrombolytic drugs for myocardial infarction and use of contraindications to treatment in the United Kingdom. DESIGN Observational study, based on a continuing audit. SETTING 39 hospitals in the United Kingdom. PATIENTS 30,029 patients admitted between November 1992 and June 1995 with suspected myocardial infarction. RESULTS Of 13,628 patients with a final di...

stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

Objectives: To compare a system of prehospital thrombolytic therapy, delivered by paramedics under medical guidance, with in-hospital thrombolytic therapy in meeting National Service Framework (NSF) targets for treatment of acute myocardial infarction at a District General Hospital setting in England. Design: Retrospective observational case-control study comparing patients with suspected acute...

Successful Treatment of Axillary-Subclavian Artery Thrombosis by Catheter-Based Thrombolytic Therapy: A Case Report

PURPOSE To determine whether subclinical cholesterol embolization is a frequent sequela of thrombolytic therapy. Case reports of catastrophic cholesterol embolization temporally associated with thrombolytic therapy in 19 patients have suggested a causal relationship. PATIENTS AND METHODS We prospectively followed 60 patients with acute myocardial infarction who underwent coronary bypass surge...

Tissue-type plasminogen activator (t-PA) is a familiar thrombolytic agent for myocardial infarction. It is perhaps natural, therefore, to think of endogenous t-PA as a "good thing" in terms of protection against coronary thrombosis or other consequences of atheroma. This view is supported by studies that showed a correlation between high concentrations of plasminogen activator inhibitor (PAI-1)...